Evidence map›Paper›PMID 12223098›Full record

ArticleThe Biochemical journal2003

The TATA-containing core promoter of the type II collagen gene (COL2A1) is the target of interferon-gamma-mediated inhibition in human chondrocytes: requirement for Stat1 alpha, Jak1 and Jak2.

Makoto Osaki, Lujian Tan, Bob K Choy, Yasuhiro Yoshida, Kathryn S E Cheah, Philip E Auron, Mary B Goldring

Open access · bronzeAbstract read
In one paragraph

Article in The Biochemical journal, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Makoto OsakiBeth Israel Deaconess Medical Center, Rheumatology Division, and New England Baptist Bone & Joint Institute, Harvard Institutes of Medicine, Boston, MA 02115, USA.
Lujian Tan
Bob K Choy
Yasuhiro Yoshida
Kathryn S E Cheah
Philip E Auron
Mary B Goldring
Beth Israel Deaconess Medical Center · USNew England Baptist Hospital · USUniversity of Hong Kong · HK

Funding

ACCESSORY CELL ACTIVATION OF THE IMMUNE RESPONSER01CA068544 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI AURON, PHILIP E · 1995 to 2004
$1.3M
REGULATION OF MATRIX GENE EXPRESSION IN CHONDROCYTESR01AR045378 · NIAMS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI GOLDRING, MARY B. · 1998 to 2001
$672k
NCI NIH HHS CA68544NIAMS NIH HHS AR45378
6 · The paper itself

Abstract

Interferon-gamma (IFN-gamma) inhibits the synthesis of the cartilage-specific extracellular matrix protein type II collagen, and suppresses the expression of the type II collagen gene ( COL2A1 ) at the transcriptional level. To further examine this mechanism, the responses of COL2A1 regulatory sequences to IFN-gamma and the role of components of the Janus kinase/signal transducer and activators of transcription (JAK/STAT) pathway were examined in the immortalized human chondrocyte cell line, C-28/I2. IFN-gamma inhibited the mRNA levels of COL2A1 and aggrecan, but not Sox9, L-Sox5 and Sox6, all of which were expressed by these cells as markers of the differentiated phenotype. IFN-gamma suppressed the expression of luciferase reporter constructs containing sequences of the COL2A1 promoter spanning -6368 to +125 bp in the absence and presence of the intronic enhancer and stimulated activity of the gamma-interferon-activated site (GAS) luciferase reporter vector, associated with induction of Stat1 alpha-binding activity in nuclear extracts. These responses to IFN-gamma were blocked by overexpression of the JAK inhibitor, JAK-binding protein (JAB), or reversed by dominant-negative Stat1 alpha Y701F containing a mutation at Tyr-701, the JAK phosphorylation site. IFN-gamma had no effect on COL2A1 promoter expression in Jak1 (U4A)-, Jak2 (gamma 2A)- and Stat1 alpha (U3A)-deficient cell lines. In the U3A cell line, the response to IFN-gamma was rescued by overexpression of Stat1 alpha, but not by either Stat1 alpha Y701F or Stat1 beta. Functional analysis using deletion constructs showed that the IFN-gamma response was retained in the COL2A1 core promoter region spanning -45 to +11 bp, containing the TATA-box and GC-rich sequences but no Stat1-binding elements. Inhibition of COL2A1 promoter activity by IFN-gamma persisted in the presence of multiple deletions within the -45/+11 bp region. Our results indicate that repression of COL2A1 gene transcription by IFN-gamma requires Jak1, Jak2 and Stat1 alpha and suggest that this response involves indirect interaction of activated Stat1 alpha with the general transcriptional machinery that drives constitutive COL2A1 expression.

Indexed as

Promoter Regions, GeneticProto-Oncogene ProteinsTATA BoxBase SequenceCell Line, TransformedChondrocytesCollagen Type IIDNAHumansInterferon-gammaInterferon-Stimulated Gene Factor 3Janus Kinase 1Janus Kinase 2Molecular Sequence DataMutagenesis, Site-DirectedProtein-Tyrosine KinasesCollagen Type IIDNAgamma interferon activation factorInterferon-gammaInterferon-Stimulated Gene Factor 3JAK1 protein, humanJAK2 protein, humanJanus Kinase 1Janus Kinase 2Protein-Tyrosine KinasesProto-Oncogene ProteinsRNA, MessengerTranscription Factors

Identifiers

PMID12223098
PMCPMC1223055
OpenAlexW2055361209

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.